Aspect Oriented Behavioral Synthesis

Modern modularization techniques such as Aspect Orientation require powerful and expressive enough specification languages in order to conceive the development of a system as the combination of the different views it is composed of. In this work we present FVS as an aspect oriented language where the composition of individual aspects is achieved employing behavioral synthesis. As a distinctive feature, our approach can handle properties denoted by non deterministic Büchi automata. A case of study is introduced to show our approach in action.XVI Workshop Ingeniería de Software.Red de Universidades con Carreras en Informátic

Aspect Oriented Behavioral Synthesis

Modern modularization techniques such as Aspect Orientation require powerful and expressive enough specification languages in order to conceive the development of a system as the combination of the different views it is composed of. In this work we present FVS as an aspect oriented language where the composition of individual aspects is achieved employing behavioral synthesis. As a distinctive feature, our approach can handle properties denoted by non deterministic Büchi automata. A case of study is introduced to show our approach in action.XVI Workshop Ingeniería de Software.Red de Universidades con Carreras en Informátic

Aspect Oriented Behavioral Synthesis

Modern modularization techniques such as Aspect Orientation require powerful and expressive enough specification languages in order to conceive the development of a system as the combination of the different views it is composed of. In this work we present FVS as an aspect oriented language where the composition of individual aspects is achieved employing behavioral synthesis. As a distinctive feature, our approach can handle properties denoted by non deterministic Büchi automata. A case of study is introduced to show our approach in action.XVI Workshop Ingeniería de Software.Red de Universidades con Carreras en Informátic

Aplicaciones inteligentes sobre internet de las cosas y grandes volúmenes de datos: un enfoque riguroso

Día tras días se generan millones y millones de nuevos datos y la cantidad de información a procesar es un desafío creciente. Entre los más destacados podemos mencionar el crecimiento exponencial de la “Internet de las cosas” o Internet of Things (IoT) en inglés en los sistemas modernos. En este sentido, no sólo el almacenamiento constante de información es un problema a resolver, sino también la extracción inteligente de información y su posterior análisis para introducir mejoras en los sistemas. Este problema ha sido atacado desde la Inteligencia Artificial y la Optimización Combinatoria, pero se han encontrado algunas debilidades como la falta de modelado y diseño y de la aplicación rigurosa de técnicas de Ingeniería de Software. Esto hace que el problema se ataque de una manera “ad-hoc”, por lo cual es necesario consolidar un enfoque de mayor formalidad en todas las etapas del proceso. La presente investigación busca aplicar técnicas formales de Ingeniería de Software como Modelado y Model Checking al manejo y análisis de grandes volúmenes de datos. Como caso de estudio concreto se trabajará con sensores para el Mantenimiento de parámetros del ambiente (como humedad o temperatura) del Laboratorio de Redes y Sistemas de Computación mediante protocolos de IoT.Eje: Agentes y Sistemas Inteligentes.Red de Universidades con Carreras en Informátic

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Título: La pastorela.

Etiqueta azul con letras doradas y logo "Regal"Estrenada en el Teatro de la Zarzuela de Madrid, el 12 de octubre de 1900 -- Estrenada en el Teatro Novedades de Madrid, el 10 de noviembre de 1926.Intérpretes: Marcos Redondo y coro general.Copia digital : BNE.Sistema de grabación eléctrica "Viva-tonal" en la etiqueta y "W" (Western Electric) grabado en el discoFuente de ingreso: César Rodríguez XaixoDatos de publicación tomados de BNE [consulta 24/05/2018

Disease-corrected haematopoietic progenitors from Fanconi anemia induced pluripotent stem cells

Premi a l'excel·lència investigadora. Àmbit de les Ciències de la Salut. 2010The generation of induced pluripotent stem (iPS) cells by ectopic expression of a defined set of factors1-5 has enabled the derivation of patient-specific pluripotent cells and provided valuable experimental platforms to model human disease6-8. Patientspecific iPS cells are also thought to hold great therapeutic potential, although direct evidence for this is still lacking. Here we show that somatic cells from Fanconi anemia (FA) patients, upon correction of the genetic defect, can be reprogrammed to pluripotency to generate patient-specific iPS cells. These cell lines appear indistinguishable from human embryonic stem cells and iPS cells from healthy individuals in colony morphology, growth properties, expression of pluripotencyassociated transcription factors and surface markers, and differentiation potential in vitro and in vivo. Most importantly, we show that corrected FA-specific iPS cells can give rise to hematopoietic progenitors of the myeloid and erythroid lineages that are phenotypically normal, i.e. disease-free. These data offer proof-f-concept that iPS cell technology can be used for the generation of disease-corrected, patient-specific cells with potential value for cell therapy applications

Proyecto piloto para el establecimiento de una red temática Interuniversitaria sobre adecuación de los estudios universitarios de Informática de las universidades públicas de Castilla y León al Espacio Europeo de Educación Superior

Resumen tomado de la publicaciónSe realiza un proyecto piloto para el establecimiento de una Red Interuniversitaria para la adecuación al Espacio Europeo de Educación Superior de la Titulación de Informática de las diferentes Universidades Públicas de Castilla y León. Se configura, se pone en marcha y se difunde de una Red Temática Interuniversitaria. Se elabora en red desde las distintas universidades participantes, una propuesta de recomendación consensuada sobre la forma de ordenar el proceso de adecuación de los estudios de Informática al esquema ECTS, especialmente en lo referente a los procesos de seguimiento y control de calidad. Se revisa, se debate y se realiza una reflexión sobre los contenidos curriculares de Informática.Castilla y LeónConsejería de Educación. Dirección General de Universidades e Investigación; Monasterio de Nuestra Señora de Prado, Autovía Puente Colgante s. n.; 47071 Valladolid; +34983411881; +34983411939;ES